Constipation, a prevalent condition in clinical practice, often presents a diagnostic and therapeutic challenge. Despite its high prevalence, it remains under-recognized and under-treated. This article aims to provide a comprehensive approach to diagnosing and treating constipation in clinical practice.
An effective diagnosis begins with a detailed patient history and physical examination. The Rome IV criteria for functional constipation can serve as a valuable tool. These criteria include infrequent bowel movements, straining, lumpy or hard stools, sensation of incomplete evacuation, and the need for manual maneuvers. It's also essential to rule out secondary causes of constipation, such as medications or underlying medical conditions.
Treatment should be individualized, considering the patient's preferences, lifestyle, and the severity of their symptoms. Initial management includes lifestyle modifications, such as increased dietary fiber intake, hydration, and physical activity. If these measures are insufficient, the next step is the use of osmotic and stimulant laxatives. For patients with refractory constipation, newer pharmacological agents like secretagogues can be considered. In severe cases, biofeedback therapy and surgery may be options.
Emerging research suggests a role for the gut microbiota in constipation. Probiotics, specifically Bifidobacterium and Lactobacillus species, have shown promise in improving bowel frequency and consistency. However, more research is needed to confirm their efficacy and determine the optimal strains and dosages.
Managing constipation requires a thorough understanding of its pathophysiology, an effective diagnostic approach, and a comprehensive, individualized treatment plan. It's crucial to consider the potential role of the gut microbiota and the possible benefits of probiotics in management. By mastering these aspects, clinicians can significantly improve their patients' quality of life.
1.
Prostate cancer detection with PET CT and PET MRI is comparable.
2.
Refractory Multiple Myeloma Responsive to Immunotherapy Plus Low-Dose Radiotherapy
3.
AI Breath Test IDs Cancers; More Grief for Prior Auth; Imatinib Discoverer Resigns
4.
In NSCLC, subcutaneous Lazertinib + Amivantamab Dosing Is Not Worse Than IV Dosing.
5.
Loncastuximab-Rituximab Boosts Response Rates in R/R Follicular Lymphoma
1.
Innovative Intraoperative Therapies in Neurosurgical Oncology: Advancing Precision and Outcomes
2.
Unlocking the Potential of Bicalutamide 50 mg: A Revolutionary New Treatment for Prostate Cancer
3.
Holistic Oncology: Advancing Survivorship, Nursing, and Innovative Cancer Care Models
4.
Emerging Chemo-Immunotherapy: New Agents and Mechanisms in Modern Oncology
5.
The Dangers of Supratherapeutic INR: The Need for Increased Awareness and Monitoring
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
3.
Asian Symposium on Advancement in Hematology and Oncology
4.
International Cancer Conference
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Thromboprophylaxis In Medical Settings
2.
EGFR Mutation Positive Non-Small Cell Lung Cancer- Case Discussion & Conclusion
3.
Recent Data Analysis for First-Line Treatment of ALK+ NSCLC
4.
Efficient Management of First line ALK-rearranged NSCLC
5.
Post Progression Approaches After First-line Third-Generaion ALK Inhibitors
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation